JP2018062523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018062523A5 JP2018062523A5 JP2017253315A JP2017253315A JP2018062523A5 JP 2018062523 A5 JP2018062523 A5 JP 2018062523A5 JP 2017253315 A JP2017253315 A JP 2017253315A JP 2017253315 A JP2017253315 A JP 2017253315A JP 2018062523 A5 JP2018062523 A5 JP 2018062523A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- hsd1
- pharmaceutically acceptable
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002401 inhibitory effect Effects 0.000 claims 28
- 239000003112 inhibitor Substances 0.000 claims 26
- 102100007777 HSD17B1 Human genes 0.000 claims 19
- 101710013449 HSD17B1 Proteins 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003098 androgen Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- -1 -OCH 2 CH 2 Br Chemical group 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 230000003388 anti-hormone Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000002035 prolonged Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 238000009094 second-line therapy Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (29)
- 被験体の癌を治療するために用いるための、請求項1〜4のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記癌がエストロゲン感受性癌である、請求項5に記載の17β−HSD1の阻害剤。
- 前記エストロゲン感受性癌が乳癌である、請求項6に記載の17β−HSD1の阻害剤。
- 前記癌がアンドロゲン感受性癌である、請求項5に記載の17β−HSD1の阻害剤。
- 前記アンドロゲン感受性癌が前立腺癌である、請求項8に記載の17β−HSD1の阻害剤。
- 二次癌療法の使用をさらに含む、請求項5に記載の17β−HSD1の阻害剤。
- 前記二次癌療法が、化学療法、毒素療法、放射線療法、ホルモンもしくは抗ホルモン療法、外科手術、凍結療法、または免疫療法からなる群から選択される、請求項10に記載の17β−HSD1の阻害剤。
- 被験体の非癌性疾患を治療するために用いるための、請求項1〜4のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記非癌性疾患が子宮内膜症である、請求項12に記載の17β−HSD1の阻害剤。
- 前記非癌性疾患が良性前立腺肥大症である、請求項12に記載の17β−HSD1の阻害剤。
- 前記非癌性疾患がアルツハイマー病である、請求項12に記載の17β−HSD1の阻害剤。
- 二次療法の使用をさらに含む、請求項12に記載の17β−HSD1の阻害剤。
- 17β−HSD1の阻害剤が少なくとも2回投与されるように用いるための、請求項5〜16のいずれか一項に記載の17β−HSD1の阻害剤。
- 静脈内、動脈内、皮下、局所的、または筋肉内に投与するように用いるための、請求項5〜16のいずれか一項に記載の17β−HSD1の阻害剤。
- 全身性に、腫瘍/疾患部位に局部的に、腫瘍/疾患部位に局所的に、腫瘍/組織血管中に、または腫瘍内に投与するように用いるための、請求項5〜16のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記癌が多剤耐性である、請求項5〜11のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記癌が転移性である、請求項5〜11のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記癌が再発性である、請求項5〜11のいずれか一項に記載の17β−HSD1の阻害剤。
- 癌の治療が、癌増殖の阻害、癌細胞の死滅、腫瘍量の減少、腫瘍サイズの減少、前記被験体の生活の質の改善、または前記被験体の生存期間の延長を含む、請求項5〜11のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記癌が、肺癌、脳腫瘍、頭頸部癌、皮膚癌、肝癌、膵癌、胃癌、結腸癌、直腸癌、子宮癌、子宮頸癌、卵巣癌、精巣癌、皮膚癌、または食道癌である、請求項5〜11のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記被験体がヒトである、請求項5〜16のいずれか一項に記載の17β−HSD1の阻害剤。
- 前記被験体が非ヒト動物である、請求項5〜16のいずれか一項に記載の17β−HSD1の阻害剤。
- 請求項27に記載の放射標識化合物またはその薬学的に許容可能な塩もしくは互変異性体からなる、放射性イメージング剤。
- 請求項27に記載の放射標識化合物またはその薬学的に許容可能な塩もしくは互変異性体からなる、乳癌または前立腺癌の治療剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161467764P | 2011-03-25 | 2011-03-25 | |
US61/467,764 | 2011-03-25 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014500216A Division JP2014508784A (ja) | 2011-03-25 | 2012-03-26 | 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018062523A JP2018062523A (ja) | 2018-04-19 |
JP2018062523A5 true JP2018062523A5 (ja) | 2018-06-07 |
JP6727184B2 JP6727184B2 (ja) | 2020-07-22 |
Family
ID=46929260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014500216A Withdrawn JP2014508784A (ja) | 2011-03-25 | 2012-03-26 | 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤 |
JP2017253315A Active JP6727184B2 (ja) | 2011-03-25 | 2017-12-28 | 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014500216A Withdrawn JP2014508784A (ja) | 2011-03-25 | 2012-03-26 | 17β−HSD1、17β−HSD3、および17β−HSD10の阻害剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11072632B2 (ja) |
EP (1) | EP2688901B1 (ja) |
JP (2) | JP2014508784A (ja) |
AU (1) | AU2012234682A1 (ja) |
CA (1) | CA2830984C (ja) |
WO (1) | WO2012129673A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014207311A1 (en) * | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
WO2014207309A1 (en) * | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1 |
CA2950800C (en) * | 2014-05-09 | 2023-01-10 | Tangent Reprofiling Limited | Modulators of androgen synthesis |
US20170260226A1 (en) * | 2014-09-11 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors |
CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
NZ760155A (en) * | 2017-06-08 | 2022-09-30 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5 |
WO2024020520A2 (en) * | 2022-07-20 | 2024-01-25 | Board Of Regents, The University Of Texas System | Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
HU214598B (hu) | 1987-09-24 | 1998-04-28 | Jencap Research Ltd | Eljárás fogamzásgátló és hormonterápiához alkalmazható, ösztrogént és progesztint tartalmazó gyógyszerkészítmények előállítására |
IL112778A0 (en) * | 1994-03-04 | 1995-05-26 | Merck & Co Inc | Substituted heterocycles, their preparation and pharmaceutical compositions containing them |
US5952319A (en) * | 1997-11-26 | 1999-09-14 | Research Triangle Institute | Androgenic steroid compounds and a method of making and using the same |
US6933312B2 (en) * | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
CN102796160A (zh) | 2005-05-26 | 2012-11-28 | 索尔瓦药物有限公司 | 17β-HSD1和STS抑制剂 |
US10174070B2 (en) * | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
EP2125859B1 (en) * | 2006-09-19 | 2013-05-15 | Abbott Products GmbH | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
CA2671075A1 (en) * | 2006-11-30 | 2008-06-05 | Solvay Pharmaceuticals Gmbh | Substituted estratrien derivatives as 17beta hsd inhibitors |
US20080171728A1 (en) | 2007-01-12 | 2008-07-17 | Quatrx Pharmaceuticals Co. | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone |
EP2014672A1 (en) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | 8-beta-substituted estratrienes as selectively active estrogens |
-
2012
- 2012-03-26 AU AU2012234682A patent/AU2012234682A1/en not_active Abandoned
- 2012-03-26 CA CA2830984A patent/CA2830984C/en active Active
- 2012-03-26 JP JP2014500216A patent/JP2014508784A/ja not_active Withdrawn
- 2012-03-26 WO PCT/CA2012/000316 patent/WO2012129673A1/en active Application Filing
- 2012-03-26 EP EP12765822.7A patent/EP2688901B1/en active Active
- 2012-03-26 US US14/007,577 patent/US11072632B2/en active Active
-
2017
- 2017-12-28 JP JP2017253315A patent/JP6727184B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018062523A5 (ja) | ||
JP2018510191A5 (ja) | ||
RU2021107754A (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
JP2015520753A5 (ja) | ||
JP2016530283A5 (ja) | ||
JP2018519245A5 (ja) | ||
JP2018516238A5 (ja) | ||
JP2019510832A5 (ja) | ||
NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
JP2016523974A5 (ja) | ||
JP2016528197A5 (ja) | ||
JP2016519653A5 (ja) | ||
JP2008535902A5 (ja) | ||
JP2016538257A5 (ja) | ||
JP2016513137A5 (ja) | ||
JP2008535903A5 (ja) | ||
JP2020517616A5 (ja) | ||
JP2008521928A5 (ja) | ||
JP2016528162A5 (ja) | ||
JP2015508103A5 (ja) | ||
JP2015511609A5 (ja) | ||
JP2015512398A5 (ja) | ||
JP2014518544A5 (ja) | ||
JP2020515582A5 (ja) | ||
JP2017514806A5 (ja) |